- Home
- HSHP vs XOMA Comparison
HSHP vs XOMA Comparison
Compare HSHP & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- XOMA
- Stock Information
- Founded
- HSHP 2021
- XOMA 1981
- Country
- HSHP Bermuda
- XOMA United States
- Employees
- HSHP N/A
- XOMA N/A
- Industry
- HSHP
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- XOMA Health Care
- Exchange
- HSHP Nasdaq
- XOMA Nasdaq
- Market Cap
- HSHP 287.7M
- XOMA 330.2M
- IPO Year
- HSHP 2023
- XOMA N/A
- Fundamental
- Price
- HSHP $6.16
- XOMA $26.96
- Analyst Decision
- HSHP
- XOMA Strong Buy
- Analyst Count
- HSHP 0
- XOMA 2
- Target Price
- HSHP N/A
- XOMA $69.50
- AVG Volume (30 Days)
- HSHP 205.0K
- XOMA 78.7K
- Earning Date
- HSHP 08-20-2025
- XOMA 08-12-2025
- Dividend Yield
- HSHP 7.14%
- XOMA N/A
- EPS Growth
- HSHP 185.76
- XOMA N/A
- EPS
- HSHP 0.28
- XOMA N/A
- Revenue
- HSHP $121,972,000.00
- XOMA $42,909,000.00
- Revenue This Year
- HSHP $11.22
- XOMA $70.91
- Revenue Next Year
- HSHP $25.90
- XOMA $14.00
- P/E Ratio
- HSHP $22.69
- XOMA N/A
- Revenue Growth
- HSHP 107.17
- XOMA 638.41
- 52 Week Low
- HSHP $4.29
- XOMA $18.35
- 52 Week High
- HSHP $9.13
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- HSHP 53.69
- XOMA 56.91
- Support Level
- HSHP $5.76
- XOMA $24.87
- Resistance Level
- HSHP $6.26
- XOMA $28.09
- Average True Range (ATR)
- HSHP 0.17
- XOMA 1.32
- MACD
- HSHP -0.07
- XOMA 0.07
- Stochastic Oscillator
- HSHP 43.32
- XOMA 70.40
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.